Sangwoo Park - 13 Dec 2023 Form 4 Insider Report for NKGen Biotech, Inc. (NKGN)

Role
Director, Other*, 10%+ Owner
Signature
/s/ Pierre Gagnon, Attorney-in-fact
Issuer symbol
NKGN
Transactions as of
13 Dec 2023
Transactions value $
$0
Form type
4
Filing time
15 Dec 2023, 21:02:22 UTC
Previous filing
10 Oct 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKGN Common Stock Gift $0 -2.5M -19.81% $0.00 10.1M 13 Dec 2023 See footnotes F1, F2
holding NKGN Common Stock 397K 13 Dec 2023 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This statement is filed by NKMax Co., Ltd ("NKMax") and Sangwoo Park ("Mr. Park"). The foregoing persons are hereinafter sometimes referred to as the "Reporting Persons." Mr. Park may be deemed to beneficially own the reported securities by virtue of the fact that Mr. Park has voting and dispositive control over the Issuer's securities held by NKMax.
F2 The filing of this statement should not be construed as an admission that Mr. Park is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of the securities held by NKMax except to the extent of his pecuniary interest therein.
F3 These shares are owned directly by Sangwoo Park.

Remarks:

NKMax may be deemed to be a director by deputization for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, by virtue of the fact that Mr. Park currently serves on the board of directors of the Issuer.